Table 6.
Multivariate analysis of Cox proportional hazards model of 5-year OS and PFS for the patients of the IC + RT group (n = 143)
| Prognostic factors | OS | PFS | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95 % CI | p value | Hazard ratio | 95 % CI | p value | |
| LMR: high versus low | 0.471 | 0.229–0.634 | 0.010 | 0.430 | 0.436–0.794 | 0.027 |
| HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA | 0.314 | 0.036–0.536 | 0.012 | 0.418 | 0.215–0.738 | 0.039 |
| Age: ≤46 versus >46 | 0.643 | 0.232–0.837 | 0.074 | 1.132 | 0.987–3.783 | 0.264 |
| FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA | 0.297 | 0.198–0.540 | 0.045 | 0.395 | 0.0245–0.740 | 0.044 |
| pathological type: SCC versus ADC versus ASC versus UDC | 0.527 | 0.186–0.640 | 0.036 | 0.397 | 0.298–0.552 | 0.023 |
| Lymph node status classification: positive lymph node versus negative lymph node | 2.586 | 0.987–4.540 | 0.073 | 2.753 | 1.747–5.394 | 0.065 |
| ALC: high versus low | 0.548 | 0.098–0.931 | 0.012 | 0.589 | 0.065–0.938 | 0.015 |
| AMC: high versus low | 0.829 | 0.152–1.730 | 0.321 | 0.771 | 0.413–2.313 | 0.421 |
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma; UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count